Validation analysis of a composite <scp>real‐world</scp> mortality endpoint for patients with cancer in the <scp>United States</scp>

Abstract

Across all cancer types analyzed, this composite mortality variable showed high sensitivity, specificity, PPV, NPV, and ±15-day agreement, and yielded median rwOS values modestly overestimated when compared to NDI-based results.